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Abstract
Background: Many people living with HIV suffer from depressive symptoms. In a previous pilot study, self-help
cognitive behavioral therapy (in booklet format) was found to be effective in treating depressive symptoms in people
with HIV. We developed an online self-help program in Dutch and English (based on the booklet) for people with HIV
and depressive symptoms. Besides the main question regarding the effectiveness of the program aimed at lowering
depressive symptoms, sub-questions will focus on the moderators of treatment success (for which patients is the
program especially beneficial?) and the mechanisms of change underlying the treatment outcome (which mediators
affect the outcome of treatment?). In this paper, the protocol of the study will be described.
Methods/design: The effectiveness of the program will be investigated by comparing the intervention group with a
waiting list-control group in a randomized controlled design, by including a pretest and three post-tests. The self-help
program contains four main components: activation, relaxation, changing maladaptive cognitions, and goal attainment.
Participants with mild to moderate depressive symptoms will work on the program for 6 to 10 weeks, during which a
coach will provide motivational support by telephone once a week. Participants in the control condition will receive
weekly minimal support from a coach for 8 weeks, and after the second post-test, they can gain access to the self-help
program. Depressive symptoms and possible mediators (e.g., activation, cognitive coping, self-efficacy, and goal
adjustment) will be assessed by self-report three times during the intervention/waiting period and at the pretest and
first post-test.
Discussion: The proposed study aims to evaluate the effectiveness of an online self-help intervention for people with
HIV and depressive symptoms. If the intervention is shown to be effective, the program will be implemented.
Consequently, many patients with HIV could be reached, and their psychological care may be improved.
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Background
Currently, HIV is a chronic disease that requires the use
of medication. Along with the physical problems that
people living with HIV (PLH) may experience (e.g.,
linked to the side effects of medication or comorbidi-
ties), psychological symptoms are also prevalent [1, 2].
Specifically, depressive symptoms are often reported by
PLH. Many PLH struggle, for example, with the daily
use of medication and thinking about whom to tell
about their HIV [3]. This and more general life stressors
may lead to depressive symptoms in PLH. In turn, PLH
with depressive symptoms have a higher chance of non-
adherence to their medication [4]. This can result in
more physical symptoms and illness. Therefore, the
treatment of depressive symptoms in PLH is important.
Various treatments are available for PLH with de-
pressive symptoms. Group and individual therapies
exist, and many of these contain cognitive behavioral
components (see review studies [5–9]). These treat-
ments are effective in decreasing depressive symptoms
and improving the quality of life in PLH [2, 5, 7–9].
Furthermore, beneficial effects were also found for
medication adherence [6].
These group and individual therapies have some disad-
vantages. First, patients and therapists should meet in
person during office hours for the treatment. Second,
the costs of these treatments are high. Third, for HIV-
specific programs, the stigma is a significant barrier to
service delivery and utilization [10]. A self-help program
could be a way to overcome these disadvantages and
barriers. The evidence base for low-intensity interven-
tions has been growing in recent years, with high-quality
trials supporting the effectiveness of self-help cognitive
behavioral therapy (CBT) for depression [11–13].
A low-cost CBT self-help booklet for PLH was devel-
oped based on prior research and a needs assessment
[14–17]. The self-help booklet contains three main com-
ponents: relaxation, changing maladaptive cognitions,
and goal attainment. The effectiveness of this booklet
was tested in a pilot randomized controlled trial (RCT)
[18]. The results indicated that this intervention was ef-
fective in reducing the depressive symptoms in PLH,
compared to waiting list controls. However, in this RCT,
25 % of the participants dropped out during the inter-
vention phase. Elements should therefore be added to
retain more PLH in the program and to increase the ef-
fectiveness. In addition, several participants indicated
they were worried that having the booklet in their home
would disclose their HIV-positive status. They would
have valued a less stigmatizing mode.
Therefore, the self-help booklet was converted into an
Internet version. The online program contains eight les-
sons, which can be completed in 6 to 10 weeks. An on-
line program has a lower stigma, is easily accessible, can
reach more people, and has lower long-term costs. Pre-
vious studies showed that online self-help therapy for
depression in people with chronic illness was effective
[19]. In addition to being converted from a booklet into
an Internet version, the program was expanded in three
ways in the proposed study:
1. An activation component was added, in which
participants will be stimulated to perform (small)
activities (e.g., wake up on time). Activation is often
used in CBT for depression as a first step [20].
2. Minimal coaching with motivational interviewing
will be offered. A meta-analysis [12] showed a
greater effectiveness of the Internet therapy when
coaching was included, also when given in a minimal
format. In addition, our recent studies including
minimal coaching showed attrition rates between 10
and 15 % [21].
3. Finally, in the current study, the online intervention
will be available in Dutch and English to reach more
PLH in the Netherlands (and possibly in other
countries in the future).
In 2014, the development of the online program was
finalized, and we asked a focus group (four volunteers
from the Dutch HIVAssociation) to evaluate the program.
Thereafter, we adapted the program, and we conducted a
pilot study with 20 PLH with depressive symptoms
(14 males; mean age = 48.65 years, SD = 10.86) to test the
feasibility of the program. Participants were approached
via advertisements on the website and in the magazine of
the Dutch HIV Association and were representative of the
Dutch HIV population. The results of the pilot study
showed that the program was effective in this small group;
depressive symptoms decreased from pre-test to post-test.
Furthermore, participants thought the program was easy
to use and helpful to them. These results encouraged us
to execute a large study on the effectiveness of the online
self-help program.
The aim of the present paper is to describe the study
protocol. The proposed study is a randomized controlled
trial; the online self-help program will be compared with
a waiting list control condition. The study will include a
pretest and three post-tests for the intervention condition
(directly after the intervention and 3 and 6 months after-
ward) and a pretest and two post-tests (directly after the
8-week waiting period and 3 months afterward) for the
control condition. After the second post-test (5 months
after the pretest), the participants in the control group
can also begin the program. Concluding, we will investi-
gate the effectiveness of the online self-help program in
decreasing depressive symptoms in the short and long
term. In addition, the moderators (for which patients is
the program especially beneficial?) and mediators (which
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mechanisms affect the outcome of treatment?) will be
assessed.
Methods/design
Design
The study is a randomized controlled trial; participants
will be randomly allocated to the intervention or the
control group. Stratified randomization by treatment
center and sex will be conducted. Stratification by sex is
conducted, as there will be more male participants in
the study, and the allocation of approximately the same
number of females to the intervention group as to the
control group is preferred. In addition, stratification by
treatment center is being conducted because the number
of (included) patients will differ among the treatment
centers. Approximately equal allocation to each of the
groups also in the small treatment centers, is important.
This will be realized by creating random number tables
for each treatment center, divided by sex. Randomization
will take place in blocks of 12 participants for each treat-
ment center. Males and females will represent separate
blocks, with six males and six females for each treatment
center, of which half will be randomly allocated to the
intervention group, and half will be allocated to the con-
trol group. Participants, coaches, and researchers cannot
be blind for allocation to conditions. Participants will be
allocated to one of the conditions after the pretest. The
random number tables will be created by an independ-
ent researcher, and the allocation sequence will be con-
cealed from the main researcher, who enrolls and
informs participants.
The design consists of multiple measurements, one
pretest, three post-tests (two in the control group), and
three assessments during the intervention/waiting
period. Figure 1 shows a flow chart of the study design,
and the SPIRIT Checklist is presented in Additional file
1. The study is approved by the medical ethics commit-
tee of the Leiden University Medical Center (LUMC; nr.
P14.091). Online informed consent will be obtained from
all participants.
Participants
At least 200 participants who are PLH with mild to
moderate depressive symptoms will be included. Par-
ticipants will be approached in 23 of the 27 HIV
treatment centers throughout the Netherlands during
their regular visits to the HIV nursing consultants
and doctors. To be eligible to participate in the
study, a participant must meet all of the following
criteria: being HIV positive, exhibiting mild to mod-
erate depressive symptoms (defined as Patient Health
Questionnaire 9 (PHQ-9) [22] score > 4 and < 20),
age 18 and older, having sufficient knowledge of the
Dutch or English language, able to access the
Internet, having an e-mail address, and available for
the next 8 weeks to work on the intervention.
An eligible participant who meets any of the following
criteria will be excluded from participation in the study:
being in the first half year following HIV diagnosis, hav-
ing severe cognitive impairments (e.g., forgetfulness),
exhibiting severe depressive symptoms (defined as PHQ-
9 score of 20 or higher), experiencing suicidal ideation
(indicated by a score > 1 on the suicide item of the
PHQ-9), showing an absence of depressive symptoms
(indicated by a PHQ-9 score of 4 or lower), undergoing
treatment presently by a psychologist or psychiatrist, or
on antidepressants for less than 3 months or has experi-
enced a change of type or dose of antidepressants in the
past 3 months. In case of severe depressive symptoms
(using the set criterion) and/or suicide ideation, patients
will be referred to their general practitioner or the HIV
treatment center.
Fig. 1 Flow chart of study design
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Sample size
A power analysis was performed (with the program
Power Analysis and Sample Size Software: PASS; [23]) to
determine the sample size needed to assess the long-
term effect of the intervention on the primary outcome
depressive symptoms. Based on a medium effect size of
0.50, which proved to be realistic according to the previ-
ous pilot RCT, and assuming an alpha of .05 and a
power of .80, both groups should consist of 64 partici-
pants who complete the four measurements. This sam-
ple size is also large enough to detect moderate pre-
defined two-way cross-product interactions, such as the
interactions of group by sex. Taking into account a drop-
out rate of 15 % during working on the self-help pro-
gram (based on our recent studies, which included
coaching [21]), at least 150 patients should be allocated
to the two groups at baseline (n = 75 in each group). We
will aim for at least 200 participants because dropout
will also occur during the follow-up.
Procedure
HIV nursing consultants and doctors in the treatment
centers will screen as many PLH as possible for the
level of depression at regular check-ups by means of
the PHQ-2 [24]. In some of the treatment centers,
the Hospital Anxiety and Depression Scale (HADS
[25]) will be used instead of the PHQ-2 because this
scale was already in use in these centers. HIV treat-
ment centers will receive information about the study
and a guideline for the screening. A form will be used
for the screening, and the forms will be sent to the
researchers. Patients will be screened over approxi-
mately 6 months; most patients visit the HIV treat-
ment center once every 6 months. If the PHQ-2
score is > 0, patients may be referred to the re-
searchers. Patients will receive written information
about the study and permission will be asked to pro-
vide the researchers with their e-mail addresses and
telephone numbers, so the researchers may contact
the patients. The researchers will provide additional
information to the patients and screen them more ex-
tensively with the PHQ-9. If the depression score is
mild (PHQ-9 > 4) to moderate (PHQ-9 < 20), patients
are eligible for the study and will be invited to par-
ticipate. After giving online informed consent, partici-
pants will be asked for permission to inform their
general practitioner and the HIV treatment center
about participation in the study. Thereafter, all partic-
ipants will complete the pretest via online question-
naires (T0). Next, participants will be randomly
allocated to either the intervention or the control
condition. At the start of the intervention, the per-
sonal coach will contact the participant by telephone
in order to check and improve motivation by using
the technique of motivational interviewing.
Subsequently, participants in the intervention group
will follow the self-help program for 6 to 10 weeks and
receive support from a coach (see study conditions).
They will be asked to fill out online questionnaires three
times during the intervention, after they complete the
program (T1, a maximum of 10 weeks after T0),
3 months later (T2), and again 3 months later (T3). Par-
ticipants who are allocated to the control condition will
receive minimal support for 8 weeks (for details see
study conditions). They will also be asked to fill out the
questionnaires, including the T2. After the T2 (which is
completed approximately 5 months after T0), the partic-
ipants will also receive the online intervention. Coaches
will monitor the well-being of participants in both
groups (see ethical precautions). We will raffle off gift
cards and iPods among the participants who completed
all questionnaires during the study.
Study conditions
Online self-help intervention
The self-help intervention is grounded in the theories of
self-regulation and stress-coping, incorporating tech-
niques of CBT and stress-management. The content of
the program reflects four main components covered in
eight lessons: activation, relaxation, changing maladap-
tive cognitions, and goal attainment. The program con-
tains a combination of psycho-education, exercises, and
assignments, all strengthened by motivation and support
to increase the effectiveness and to minimize the attri-
tion over time.
The intervention is offered through a secured web-
site that contains the complete work program. Partici-
pants work on the intervention 1-2 hours a week for
a period of 6-10 weeks. The program starts with an
introduction, and participants are asked to think of a
small activity to perform (e.g., taking a short walk;
lesson 1). They are stimulated to perform this activity
in the following weeks and to expand this to other
activities. Furthermore, participants will be instructed
to do relaxation exercises and to continue these exer-
cises in the coming weeks (lesson 2). Thereafter, par-
ticipants learn to identify and change irrational
cognitions (by challenging negative thoughts) and to
evoke a strong and positive feeling when they experi-
ence negative feelings (lessons 3-5). Furthermore, par-
ticipants are guided to formulate a new, realistic,
concrete goal (such as quit smoking) and work on
the stepwise attainment of this goal (lessons 6-7). Fi-
nally, the participant will work on a concluding and
summarizing lesson (lesson 8). All participants will
receive support from a coach during the intervention
(see below).
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Waiting list control condition
Participants randomized to the control group will be
placed on a waiting list and will receive the intervention
after T2. They will receive an initial phone call to ex-
plain the procedures (to minimize attrition). Participants
will receive minimal support from a coach (see below).
Support from a coach
Participants in the intervention group will be allocated
to a coach, who will provide motivation and support
throughout the program. During the first telephone con-
tact, the coach will introduce the program, motivate the
participant, and address technical aspects. Once a week,
a prescheduled telephone call of approximately 15 mi-
nutes will be arranged between the participant and the
allocated coach. Coaching will be provided through
queries about the participant’s progress, motivational
remarks, support in case problems are encountered,
and encouragement to continue the program. Coach-
ing will not include formal psychotherapy and will be
provided until the participant completes the program
or for a maximum of 10 weeks. If the participant is
not finished with the program after 10 weeks, the
coaching will end, but the participant can continue the
program.
Participants in the control group will also be allocated
to a coach, who will provide minimal support over
8 weeks. Participants will have a pre-scheduled weekly
telephone call of approximately 5 minutes with the
coach. The coach will address the well-being of the par-
ticipant. Coaches will try to prevent participant dropout
and monitor their depressive symptoms. When depres-
sive symptoms or suicidal thoughts increase, the coach
will act appropriately (see ethical precautions).
A protocol for coaching will be used, with guidelines
available for the provision of support. Coaches will re-
ceive a short training to inform them about the study
and the coaching procedures. After each telephone call,
coaches will note the elements that were used during
the call (e.g., motivation, support) to monitor treatment
integrity. Coaches will be Master students in clinical
psychology or individuals with a Master’s degree in the
field of psychology. The coaches will have completed
clinical courses during their Master’s degree program in
which they learned communication skills, interview
techniques, and treatment strategies. In addition, coa-
ches will be selected in a personal interview on the basis
of adequate communication skills for the support and
motivation of participants. Coaches will be supervised by
the researchers and a psychotherapist. Once every
2 weeks (every week during the first month of the
study), the coaches and the main researcher will hold an
intervision meeting. Coaches can discuss difficulties and
questions with each other and the researcher. If a
problem arises between intervision sessions, the coach
may contact the researcher. The researcher and the
coach can consult a psychotherapist if necessary.
Ethical precautions
Coaches will monitor the well-being of participants in
both the intervention and control groups. Each week,
they will ask how the participant is doing. When depres-
sive symptoms worsen or when suicidal thoughts in-
crease, the coach will discuss this with the participant.
The coach can refer the participant to the general practi-
tioner or the HIV treatment center, if necessary. The
coach can discuss this with the researcher and the psy-
chotherapist. When a participant is referred for more
intensive treatment from a psychologist or psychiatrist,
the participant may continue with the study. As this may
influence the outcomes, the referral will be added as a
covariate in the analysis.
Participants will complete questionnaires to assess de-
pressive symptoms during the course of the study. When
depressive symptoms of a participant increase, the re-
searcher will notify the coach about this. The coach will
discuss this increase of symptoms with the participant
and will act appropriately. These guidelines are also
described in the protocol for coaches.
Assessments
All assessments are self-reports and will be conducted
online (except for the PHQ-2, which will be on paper for
screening by the HIV nursing consultants and doctors
and the PHQ-9, which will be used by the researchers
for screening by telephone). Table 1 depicts all the as-
sessment instruments that will be used in each stage of
the study. The primary outcome is depression severity,
as measured by the PHQ-9 [22] and the Center for
Epidemiologic Studies Depression Scale (CES-D [26]).
Secondary outcomes are physical tension, activation
(Behavioral Activation for Depression Scale (BADS) [27]),
cognitive reappraisal (Emotion Regulation Questionnaire
(ERQ) [28]), cognitive coping (Cognitive Emotion
Regulation Questionnaire (CERQ) [29]), depressive
thoughts (Crandell Cognitions Inventory (CCI) [30]),
behavioral coping (Behavioral Emotion Regulation
Questionnaire (BERQ) Kraaij & Garnefski, unpublished
questionnaire), coping self-efficacy (Kraaij & Garnefski,
unpublished questionnaire), goal adjustment (Goal
Disengagement and Reengagement Scale [31]), personal
growth (Garnefski & Kraaij, unpublished questionnaire),
symptoms of anxiety (Generalized Anxiety Disorder 7
(GAD-7) [32]), negative life events (Life Events Scale,
[33]), motivation to start with the intervention, compli-
ance, dropout and reasons for dropout, medical data,
and user satisfaction.
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As potential moderators of treatment outcome
demographic variables (sex, age, education, and na-
tionality), clinical and psychological characteristics
(severity of depressive symptoms at baseline, anxiety
symptoms at baseline, coping self-efficacy, physical
health, HIV status, motivation, and alcohol and drug
use) will be tested at first. Previous research indicated
that some of these moderators (e.g., sex and baseline
depression severity) might be important in online
CBT for depression [34, 35]. In addition, other pos-
sible moderators will be investigated exploratory.
The mediator variables and the dependent variable will
be measured three times during the intervention/waiting
period, at the pretest, and at the first post-test. The fol-
lowing mediator variables will be assessed in the study:
activation (two items of the BADS), physical tension
(two items), cognitive reappraisal (two items of the
ERQ), cognitive coping (12 items of the CERQ), goal ad-
justment (two items of the Goal Disengagement and Re-
engagement Scale), symptoms of anxiety (PHQ-4 [36]),
and coping self-efficacy (two items). The dependent vari-
able in the mediational analysis is the depressive symp-
toms (PHQ-4). The questions (regarding, for example,
symptoms and cognitions) that will be asked during the
intervention/waiting period will refer to the last week.
The assessments will be administered three times during
Table 1 Overview of assessments during the study
Assessment Screening HIV
treatment centers
(+/- 5 minutes)
Screening
researchers
(+/- 10 minutes)
T0: Pretest
(+/- 25 minutes)
Three times during
intervention
/waiting period
(+/- 10 minutes)
T1: post intervention
/waiting
period: 6-10
weeks after T0
(+/- 20 minutes)
T2: 3-month
follow-up
(+/- 20 minutes)
T3: 6-month
follow-up1
(+/- 20 minutes)
PHQ-2 or HADS X - - - - - -
PHQ-9 - X X - X X X
CES-D - - X - X X X
Demographics
and other
information
- - X - X X X
Physical tension
questionnaire
- - X X X X X
BADS - - X X X X X
ERQ - - X X X X X
CERQ - - X X X X X
CCI - - X - X X X
Self-efficacy
questionnaire
- - X X X X X
Goal
disengagement
and
reengagement
scale
- - X X X X X
BERQ - - X - X X X
Personal growth
questionnaire
- - X - X X X
GAD-7 - - X - X X X
PHQ-4 - - - X - - -
Life Events Scale - - X - X X X
Motivation - - X - - - -
Compliance - - - X X X1 X
Dropout - - - X X X X
Medical data - - X - - - X
User satisfaction
questionnaire
- - - - X - -
PHQ-2 Patient Health Questionnaire 2, HADS Hospital Anxiety and Depression Scale, PHQ-9 Patient Health Questionnaire 9, CES-D Center of Epidemiologic Studies
Depression Scale, BADS Behavioral Activation for Depression Scale, ERQ Emotion Regulation Questionnaire, CERQ Cognitive Emotion Regulation Questionnaire, CCI
Crandell Cognitions Inventory, BERQ Behavioral Emotion Regulation Questionnaire, GAD-7 Generalized Anxiety Disorder 7, PHQ-4 Patient Health Questionnaire 4
1Not sent to participants in the control group
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the intervention/waiting period because, at these mo-
ments, we expect change in the mediating variables. The
assessments are linked to the lessons of the self-help
program for participants in the intervention group. At
the first measurement, we expect a change in the behav-
ioral activation; at the second measurement, we expect a
change in the physical tension; at the third measure-
ment, we expect a change in the cognitive reappraisal
and cognitive coping; and at the post-test, we expect a
change in the goal adjustment. Coping self-efficacy and
anxiety are expected to change over the entire course of
the treatment.
Patient Health Questionnaire 9 (PHQ-9)
Depressive symptoms will be measured with the PHQ-9
at the pre- and post-tests [22]. The questionnaire con-
sists of nine items and includes the DSM-V criteria for a
major depressive disorder. The items are rated on a
four-point scale ranging from 0 “not at all” to 3 “nearly
every day,” e.g., “Over the last two weeks, how often
have you been bothered by: little interest or pleasure in
doing things?” Scores range from 0 to 27, and cutpoints
of 5, 10, 15, and 20 represent mild, moderate, moder-
ately severe, and severe levels of depressive symptoms.
The PHQ-9 is sensitive to change, has good sensitivity
and specificity for detecting depressive disorders, and
has adequate psychometric properties [37]. Furthermore,
the questionnaire is often used with PLH [38]. This
questionnaire will be used to screen participants on de-
pressive symptoms and to measure change in depressive
symptoms from baseline to the post-tests.
Center of Epidemiologic Studies Depression Scale (CES-D)
The CES-D [26] will be used to measure depressive
symptoms during the past week. The questionnaire con-
sists of 20 items, such as “During the past week: I felt
sad.” Items are rated on a four-point scale ranging from
0 “rarely or none of the time (less than 1 day)” to 3
“most or all of the time (5-7 days).” Total scores can
range from 0 to 60, and the cut-off score for clinical de-
pression is 16. The internal consistency, reliability, and
convergent validity of the CES-D are adequate [26, 39],
and sensitivity and specificity are high [40]. Furthermore,
the questionnaire is often used with PLH [41]. We will
use this questionnaire to measure the change in depres-
sive symptoms from the pretest to the post-tests.
Demographic variables and other information
A self-designed questionnaire will be used to ask partici-
pants about sex, age, educational level, nationality, mari-
tal status, sexual orientation, social support, disclosure
of HIV positive status, alcohol and drug use, previous
depressive and anxiety episodes, treatment of psycho-
logical symptoms, and physical health. This information
will be used to describe the demographic and clinical
characteristics of the sample. In the follow-up assess-
ments, questions will be asked about the use of medica-
tion for psychological problems and treatment received
from a psychologist or a psychiatrist since the start of
the study. The use of medication and treatment received
will be added as covariates in the analysis.
Furthermore, participants will complete a self-
designed questionnaire about information regarding the
HIV infection. Questions include time since the HIV
diagnosis, how the infection occurred, symptoms of the
infection, cluster of differentiation 4 (CD4) cell count,
viral load, use of highly active antiretroviral therapy
(HAART), medication adherence, and side effects of the
medication. This information will be used to describe
the HIV status and use of HAART by the sample.
Physical tension questionnaire
Physical tension will be measured with a self-designed
10-item questionnaire. Questions include difficulty to
relax, ways to relax, and symptoms of physical tension
(e.g., trembling hands, tense neck and shoulder muscles,
and increased heart rate). Items can be answered on a
three-point scale (no, sometimes, and yes). Higher scores
reflect less physical tension.
Behavioral Activation for Depression Scale (BADS)
The subscale activation of the BADS [27] will be used to
measure activation during the past week. The subscale
consists of seven items that will be measured on a
seven-point scale ranging from 0 “not at all” to 6 “com-
pletely,” e.g., “I am content with the amount and types
of things I did.” Higher scores reflect greater levels of ac-
tivation. The psychometric properties of the Dutch
BADS are adequate [42].
Emotion Regulation Questionnaire (ERQ)
The reappraisal subscale of the ERQ [28] will be used to
measure the cognitive reappraisal. The six items are
rated on a scale ranging from 1 “strongly disagree” to 7
“strongly agree,” e.g., “When I want to feel less negative
emotion, I change the way I’m thinking about the situ-
ation.” Higher scores indicate that cognitive reappraisal
is often used to regulate emotions. The convergent and
discriminant validity of the ERQ are adequate [28].
Cognitive Emotion Regulation Questionnaire (CERQ)
The subscales rumination, catastrophizing, positive re-
focusing, refocus on planning, positive reappraisal, and
putting into perspective of the CERQ [29] will be used
to measure the use of these cognitive coping strategies
when thinking about having HIV. The subscales consist
of four items each, which will be rated on a five-point
scale ranging from 1 “(almost) never,” to 5 “(almost)
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always.” Higher scores on a subscale indicate that this
cognitive coping strategy is often used when thinking
about having HIV. Examples of items include “I keep
thinking about how terrible it is that I have HIV” (cata-
strophizing) and “I think about pleasant experiences”
(positive refocusing). The psychometric properties of the
CERQ are adequate [43].
Crandell Cognitions Inventory (CCI)
The hopelessness subscale of the CCI [30] will be used
to measure black and white depressive thoughts. The
subscale consists of seven items that are rated on a five-
point scale ranging from 1 “(almost) never” to 5 “(al-
most) always,” e.g., “I’ll never feel good again.” Higher
scores indicate a higher frequency of black and white de-
pressive thinking. The reliability and validity of the CCI
are good [30, 44].
Coping self-efficacy questionnaire
Self-efficacy to cope with having HIV will be measured
with a self-designed eight-item questionnaire (Kraaij &
Garnefski, unpublished questionnaire). The question-
naire is based on the Generalized Self-Efficacy Scale,
which has a good reliability and validity [45]. Items will
be measured on a five-point scale ranging from 1 “totally
disagree” to 5 “totally agree,” e.g., “I have the necessary
skills to deal with having HIV.” High scores reflect more
self-efficacy to cope with having HIV.
Goal Disengagement and Reengagement Scale
Goal adjustment will be measured with the Goal Disen-
gagement and Reengagement Scale [31]. We slightly
adapted the scale so that questions will be asked regard-
ing the disengagement and reengagement of goals that
one has to stop pursuing because of having HIV. The
scale consists of four items that measure goal disengage-
ment (e.g., “If I have to stop pursuing an important goal
in my life because I have HIV, it’s easy for me to reduce
my effort toward the goal”) and six items that measure
goal reengagement (e.g., “If I have to stop pursuing an
important goal in my life because I have HIV, I start
working on other new goals”). Items are measured on a
five-point scale ranging from 1 “totally disagree” to 5
“totally agree.” Higher scores indicate more goal disen-
gagement and reengagement. A question about new
goals that have already been found will be added: “I have
already found new goals.” This last question will be han-
dled separately, with higher scores indicating that more
new goals were found.
Behavioral Emotion Regulation Questionnaire (BERQ)
The subscales seeking distraction, actively approaching,
seeking social support, and withdrawal from the BERQ
(Kraaij & Garnefski, unpublished questionnaire) will be
used to measure the use of these behavioral strategies to
cope with having HIV. Each subscale consists of four
items that will be measured on a five-point scale ranging
from 1 “never/hardly ever” to 5 “(nearly) always,” e.g., “I do
other things to distract myself.” Higher scores on a sub-
scale indicate that the strategy is often used to cope with
having HIV. A previous study (Kraaij & Garnefski, in prep-
aration) has shown a good reliability of this questionnaire.
Personal growth questionnaire
Personal growth due to having HIV will be measured
with a self-designed five-item questionnaire (Garnefski
& Kraaij, unpublished questionnaire). Items will be rated
on a five-point scale ranging from 1 “not at all” to 5
“certainly,” e.g., “Because of having HIV I appreciate life
more.” High scores indicate personal growth due to hav-
ing HIV. In a previous study, the reliability of this ques-
tionnaire was adequate [15].
Generalized Anxiety Disorder 7 (GAD-7)
The severity of symptoms of anxiety will be investigated
with the GAD-7 [32]. The questionnaire consists of
seven items that are rated on a four-point scale ranging
from 0 “not at all” to 3 “nearly every day,” e.g., “Over the
last 2 weeks, how often have you been bothered by: feel-
ing nervous, anxious or on edge.” Higher scores indicate
more anxiety symptoms. The psychometric properties of
the GAD-7 are adequate, and the scale also may be used
as a screener for panic, social anxiety, and post-
traumatic stress disorder [37].
Patient Health Questionnaire 2 and Patient Health
Questionnaire 4 (PHQ-2 and PHQ-4)
The PHQ-4 [36] will be used to assess depressive and
anxiety symptoms during the intervention or waiting
period (for the mediational analysis). It consists of the
first two questions of the PHQ-9 and the first two ques-
tions of the GAD-7. Items are rated on a four-point
scale ranging from 0 “not at all” to 3 “nearly every day.”
Higher scores indicate more pathology. The internal reli-
ability, construct validity, and factorial validity are ad-
equate [36]. The PHQ-2 [24] consists of the first two
questions of the PHQ-9 and will be used by the HIV
treatment centers to screen for depressive symptoms.
Hospital Anxiety and Depression Scale (HADS)
The HADS [25] will be used by some of the HIV treat-
ment centers to screen for depressive symptoms. The
HADS consists of an anxiety and a depression subscale,
and each subscale consists of seven questions, e.g., “I still
enjoy the things I used to enjoy.” Items are rated on a
four-point scale, and the response categories are differ-
ent for each question. Higher scores indicate more anx-
iety and depressive symptoms. The HADS is widely used
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and is a reliable and valid questionnaire to screen for
anxiety and depressive symptoms [25, 46].
Life Events Scale
Life events will be assessed with the Life Events Scale
[33]. The scale consists of 17 negative life events (e.g.,
divorce of parents), and participants indicate if they have
not experienced the life event, experienced it longer than
1 year ago, or experienced it last year. For each of the
two periods, a total score of negative life events will be
calculated.
Motivation to start with the intervention
Three questions will be used to measure the motivation
to start the intervention. Two questions will be asked re-
garding the expected usefulness of the intervention, and
one question about the motivation to start with the
intervention. Questions will be answered on a five-point
scale, and the scores on the items will be summed.
Compliance
Two measures of program adherence will be used in this
study. During the intervention, program adherence will
be measured three times by asking participants whether
they read the information on the website and performed
the exercises. Furthermore, we will monitor whether the
participant calls with the coach. These two measures will
be handled separately.
Dropout and reasons for dropout
Two types of dropout will be investigated three times
during the intervention and at T1, T2, and T3. We will
register the participants who stopped using the interven-
tion and the participants who did not complete the
questionnaires. We will remind participants to fill in the
questionnaires. When they drop out, we will ask them
why they do not wish to participate anymore to investi-
gate the reasons for dropout. We will examine the differ-
ence in dropout between groups and differences
between participants who completed and stopped using
the intervention.
Medical data
Medical data will be obtained from the Athena/SHM
Cohort Study after consent from the participant. The
ATHENA Cohort Study is maintained by Stichting HIV
Monitoring, which is supported by the Dutch Ministry
of Health via the National Institute for Public Health
and Environment (RIVM). The data that will be used in-
clude the time since HIV diagnosis, medication use,
CD4 cell count, and viral load.
User satisfaction questionnaire
At T1, we will ask participants about their satisfaction
with the self-help program and the coach with a self-
designed questionnaire. The questionnaire consists of 31
items to evaluate the intervention, for example, the com-
ponents of the self-help program and the support from
the coach. Open-ended and closed-ended questions will
be used in the questionnaire. The questions for partici-
pants in the control group will concern the support from
the coach (13 questions). The answers to these questions
will be used to adjust the self-help program before
implementing it.
Statistical analyses
A two-tailed alpha of .05 will be used for significance
testing. All analyses will be based on an intention-to-
treat (ITT) analysis, which includes all participants who
were randomized to one of the groups at the beginning
of the study [47]. Baseline differences between condi-
tions will be investigated with chi-square tests for cat-
egorical variables and ANOVAs for continuous variables.
To examine the effect of condition on the depressive
symptoms at the post-tests, longitudinal multilevel re-
gression analysis (LMRA) will be conducted [48]. A two-
level model will be studied: time at level 1 and partici-
pants at level 2. The variable time will have four categor-
ies indicating the four time points (T0–T4). The
baseline (T0) will be used as reference category. The in-
dependent variable is condition, the dependent variable
is the score on the PHQ-9 or the CES-D, and several co-
variates will be included in the model (e.g., sex and age).
Multiple imputation for missing data is not necessary in
LMRA because it can include participants with missing
data on one or more time points [48]. The existence of
an effect of HIV treatment center will be investigated
exploratory.
Furthermore, Cohen’s d will be calculated to indicate
within- and between-group effect sizes [49]. In addition,
clinically important differences for individual change in
depressive symptoms will be examined. Change scores
of 5 or more from the pretest to the post-tests will be
considered as clinical important differences for the
PHQ-9 [50].
With regard to all secondary outcomes, we will study
the pre-treatment versus post-treatment changes by
using the analyses described above for the PHQ-9 and
the CES-D. To examine moderators of the treatment
outcome, LMRA will be conducted. Potential modera-
tors will be entered individually. Interaction effects will
be investigated (e.g., time x condition x moderator). A
limited number of cross-product interactions will be ex-
amined, and we will correct for multiple testing. Further-
more, the QUINT (Qualitative Interaction Trees [51])
method will be used to identify subgroups for which the
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intervention is most effective, by exploratory investiga-
tion of the multiple moderators.
Mediation will be tested by examining the indirect ef-
fect of the independent variable (condition) on the
dependent variable (depressive symptoms) through the
proposed mediators. Mediation analysis will be con-
ducted by using latent difference score models, which
are recommended with repeated measurements and
multiple mediators [52]. These models focus on intra-
individual change and individual differences in that
change.
Discussion
In the proposed study, we will investigate the effective-
ness of an online self-help intervention for PLH with de-
pressive symptoms in a randomized controlled trial.
Additionally, moderators and mediators of the treatment
outcome will be assessed. This study has some strengths
and limitations that will be discussed in the following
section. First, a strength of this study is that the self-help
program is online, so many people can be reached. Only
PLH without Internet or an e-mail address cannot par-
ticipate, but most people in The Netherlands have access
to the Internet. Second, participants can work on the
program when and where they want and at their own
pace. Third, the content of the program is based on
prior research and a needs assessment among PLH [14–
18]; that is, the program is designed especially for PLH.
Fourth, moderators of the treatment outcome will be
studied; we will investigate for whom the program is es-
pecially beneficial. Investigations of the effect of personal
characteristics on the treatment outcome are useful, so
patients could receive the treatment that is most likely
to decrease their depressive symptoms. Fifth, mediators
of the treatment outcome will be assessed; the mecha-
nisms of change of the intervention will be studied.
Knowing more about exactly how the invention works is
important. Knowing what is effective would allow the
adaptation of the treatment to make it more efficient
[53]. Sixth, the support participants receive from the
coach is also a strength in this study. The coach will mo-
tivate participants to continue with the program, and
this will probably decrease the dropout. Lastly, most
HIV treatment centers in the Netherlands agreed to
screen patients for the study. This means that we will
have PLH from across the country participating in the
study.
Furthermore, some limitations are present in the
study. Patients with severe depressive symptoms and/or
suicidal ideation will be excluded from the study. We
argue that these patients should be closely monitored by
a therapist. We expect that these patients would benefit
from the self-help program, as has also been found in
previous research [54], but more intense treatment is
desirable for these patients. In addition, the follow-up
period of participants in the control group is only
3 months (they may start with the intervention after the
3-month follow-up), while this period is 6 months for
the participants in the intervention group. However, we
argue that it is not ethical to let people in the control
group wait for approximately 8 months before providing
the intervention (8 weeks plus 6 months of follow-up).
Therefore, the intervention will be offered to the control
group after the second post-test. The last limitation con-
cerns the screening of participants for depressive symp-
toms. We will use a questionnaire with nine items to
measure depressive symptoms in PLH. One could argue
that a diagnostic interview will screen depressive symp-
toms more extensively and allow the identification of a
possible depressive disorder. However, this approach
would be time consuming, and the PHQ-9 is a reliable
and valid measure of severity of depressive symptoms
[37]. Furthermore, the program is designed for people
with mild to moderate depressive symptoms, so a diag-
nosis of depression is not an inclusion criterion for par-
ticipation in the study.
To conclude, in the proposed study, we will evaluate
an online self-help program for PLH with depressive
symptoms. Since depressive symptoms exist frequently
in PLH, low-cost and low-stigmatizing interventions are
needed for these individuals. The proposed study offers
an online self-help program that complies with this re-
quest. If the self-help program proves to be effective in
the proposed study, implementation of the website will
be done in cooperation with the Dutch patient
organization (HIV Vereniging Nederland) and HIV
treatment centers. Furthermore, the program may be
implemented in other countries as well.
Trial status
Patient recruitment is completed.
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